[New possibilities for reparative therapy of dry eye syndrome]. / Novye vozmozhnosti reparativnoi terapii sindroma «sukhogo glaza¼.

In recent years, among artificial tear preparations that have additional metabolic properties, in addition to moisturizing the ocular surface, there has been a drug Optinol Soft Recovery (LLC JADRAN). In addition to 0.15% sodium hyaluronate, it contains 2% dexpanthenol, which stimulates reparative regeneration of the corneal epithelium, in particular in patients with dry eye syndrome (DES). PURPOSE: This study evaluates the clinical efficacy of the drug Optinol Soft Recovery in the treatment of patients with DES accompanied by xerotic changes in the corneal epithelium. MATERIAL AND METHODS: The study included 82 patients (15 children and 65 adults) with moderate and severe DES accompanied by the following corneal pathology: filamentous keratitis (20 patients, 33 eyes), persistent corneal erosion (28 patients, 49 eyes) and punctate keratopathy (34 patients, 68 eyes). RESULTS: All patients receiving fourfold instillations of the studied drug were observed already during the first 7 days to have increased stability of the tear film and decreased severity of staining of the cornea and conjunctiva with vital dyes (0.1% sodium fluorescein and 3% lissamine green, respectively). Further, as the patients were transferred to an individual instillation regimen, a progressive decrease in the Ocular Surface Disease Index (OSDI), an increase in corneal sensitivity and tear meniscus index were also recorded. The differences in most parameters of the course of xerosis compared to the initial ones were statistically significant starting from day 10-20 of therapy, depending on the initial severity of corneal xerosis (p<0.05-0.001). CONCLUSION: Patients with moderate DES complicated by punctate keratopathy were the most susceptible to therapy with the drug Optinol Soft Recovery, while patients with filamentous keratitis secondary to a severe clinical form of DES were the least susceptible.

[Risk factors, clinical features and indications for treatment of dry eye disease at a young age]. / Faktory riska, osobennosti klinicheskoi kartiny i pokazaniya k lecheniyu sindroma «sukhogo glaza¼ v molodom vozraste.

In recent decades, there has been an increase in the prevalence of dry eye disease (DED) not only in older people, but also in young people, which is potentially associated with the use of digital devices. Early detection of signs of DED and the appointment of preventive tear replacement therapy can help stabilize the tear film and slow down the progression of the disease. PURPOSE: To study risk factors, prevalence and clinical manifestations of DED in young people, to determine indications and evaluate the effectiveness of treatment with artificial tears. MATERIAL AND METHODS: The study included 91 patients aged 21 to 39 years (mean age 22.4±0.35 years), 63 (69.2%) women and 28 men (30.8%). All patients had tear film breakup time (TBUT) measured and underwent Schirmer I test, LIPCOF, ocular surface staining with vital dyes, lacrimal OCT-meniscometry and filled a questionnaire. To determine the effectiveness of the tear replacement therapy, 45 people prescribed sodium hyaluronate solution were randomly selected. RESULTS: The time that study subjects spend using devices ranged from 6 to 18 hours per day, amounting to 11.5±0.35 hours on average. According to the results of the Ocular Surface Disease Index (OSDI) questionnaire, 92.9% of study participants were revealed to have subjective symptoms of eye irritation. A decrease in TBUT was recorded in 30.8% of cases, the results of the Schirmer I test were decreased in 82.4% of the subjects. Significant changes in OSDI, Schirmer test and TBUT were obtained as the result of treatment. Changes in the indicators of staining and OCT meniscometry were not reliable. CONCLUSION: The most significant risk factor of developing DED at a young age is regular, prolonged visual work with digital screens. The main symptoms are subjective manifestations and TBUT.

[The parents evaluation of accessibility of out-patient ophthalmologic care in Chelyabinsk].

Every year number of eye diseases among children and adolescents is steadily increasing. The most possible causes of this process are sedentary life-style, computerization of society and school curriculum characteristics. The survey of 209 parents of children and adolescents was organized and carried out. The study established that modern children spend much more time at screens than it is recommended by regulatory documents. The pathology of eye was diagnosed in 46.9% of children, 39.2% of children are regularly observed by ophthalmologist. 53.6% of children are regularly observed by an ophthalmologist. Among parents whose children are monitored by ophthalmologist, 55.3% mentioned inaccessibility of medical appointments, that makes impossible regular corresponding medical check-ups and results in progressing of diseases present and development of new ones. The ophthalmologist plays key role in maintaining visual analyzer health. To effectively prevent visual organ pathology, it is necessary to achieve comprehensive interaction of ophthalmologist, teachers (preschool teachers), parents and children themselves.

[Effectiveness of 3-hydroxypyridine and succinic acid derivatives in complex treatment of primary open-angle glaucoma].

Prospective, placebo-controlled, single-blind, randomized clinical investigation of the influence of domestic 3-hydroxypyridine and succinic acid derivatives (emoxipin, reamberin, mexidol) on the effectiveness of a complex treatment of primary open-angle glaucoma (POAG) has been performed in a group of patients. It is established that intravenous infusion of 3-hydroxypyridine derivatives (emoxipin and mexidol) for two weeks, beginning 14 days after the start of POAG treatment, produced a retinoprotective action, with three months postponed changes in the central retinal artery (CRA) blood velocity. The retinoprotective effect of emoxipin (single dose, 150 mg) was manifested by reduction in the horizontal size of blind spot in two weeks, with the subsequent reduction of the CRA end-diastolic blood velocity observed three months after finish of the infusion therapy. The administration of mexidol (single dose, 300 mg) after 14 days of treatment led to widening of the summarized field of vision (test-object square, 16 mm), accompanied by a decrease in the electrosensitivity threshold of the optic nerve and the intensity of POAG-associated hypothymia. All indices of CRA blood velocity increased three months after termination of mexidol infusions. Reamberin (single dose, 400 ml 1,5% solution of reamberine, containing polyelectrolyte and meglumine succinate mixture) did not show retinoprotective action, but caused proatherogenic changes of blood lipids and 3 months postponed CRA end-diastolic blood velocity increase. The effect of mexidol (which is a derivative of both 3- hydroxypyridine and succinic acid) exceeds that of separate 3-hydroxypyridine (emoxipin) and succinic acid (reamberin) derivatives in the degree of retinoprotection and positive effect on the optic nerve condition and mood of POAG patients.

[The influence of water soluble antioxidant agent (mexidol) on optic nerve and blood flow velocity in ocular and orbital arteries in patients with primary open-angle glaucoma].

The prospective single-blind placebo-controlled randomized trial is devoted to influence of mexidol (2-ethil-6-methil-3-hydroxipiridine succinate) on dynamics of optic nerve electrophysiologic profile and velocity indices of blood flow in ocular and orbital arteries in correlation with changes of retinal photosensitivity, visual acuity and visual field size during course of intravenous mexidol infusions and standard treatment of primary open-angle glaucoma. 2 weeks of intravenous infusions of 300 mg mexidol daily was found to cause depression of optic nerve electrical sensitivity threshold and widening of total visual field (16 mm2 test stimulus) after 14 days of treatment. These effects were not associated with changes of blood flow velocity in ocular and orbital arteries, were transient and came to initial indices 3 months after the end of treatment. Delayed vasotropic effect of mexidol manifested in increase of blood flow velocity in central retinal artery in 90 days after the end of infusions.